Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.
- Existing GSS directors would resign if BCAL nominees secure a board majority
- BCAL’s largest shareholder bought 4.8% of GSS
- GSS has A$20.9 million and 21.3 quarters of funding available
- BCAL reported A$1.6 million and 2.6 quarters of funding
- GSS continues to support proposed Microba merger discussions
GSS Sets a Board Control Consequence
Genetic Signatures Limited (ASX:GSS) has raised the stakes ahead of its 28 October extraordinary general meeting, warning that any current director who remains on the board will resign immediately if BCAL Diagnostics’ two nominees become a majority. The proposed nominees are Susan Forrester and Dr John Melki.
The announcement turns a contested board vote into a direct test of who will control GSS’s strategic direction. The company says the existing board is needed to guide its proposed Microba transaction and warns that a wholesale change at this point could create instability and disruption.
Cash Runway Fuels Merger Speculation
GSS is pressing BCAL to state unequivocally whether it intends to merge with GSS before 1 December 2027. BCAL has described GSS as a “complementary molecular diagnostics company”, but GSS says BCAL’s latest reported cash position of approximately A$1.6 million and estimated funding of 2.6 quarters invite questions about its longer-term intentions.
By comparison, GSS reported approximately A$20.9 million in cash and 21.3 quarters of available funding in its latest quarterly report. GSS says it suspects BCAL may seek a merger, but that remains an inference from GSS rather than a stated BCAL position. The company has invoked ASIC’s “truth in takeovers” policy as the basis for its demand for a clear statement.
Shareholding Adds Pressure to the Contest
That question has become more pointed since BCAL’s largest shareholder, Capital Property Corporation, bought 10,988,711 GSS shares, or approximately 4.8%, on 2 October. GSS says the combined holding of BCAL and Capital Property now stands at 23.3%, although it is still considering its position on that figure.
The timing also features prominently in GSS’s argument: BCAL first provided, but did not validly serve, a section 249D request five days after GSS announced its Microba merger discussions with Microba Life Sciences. GSS continues to frame that proposed transaction as a central reason for retaining the current board.
Revenue Comparison Sharpens the Strategic Dispute
GSS’s filing contrasts its operating scale with BCAL’s. GSS reported consolidated revenue of A$14.84 million in FY2026, while Microba reported A$14.76 million and BCAL A$182,510. Quarterly customer receipts show a similar gap: GSS recorded A$2.99 million in the June 2026 quarter, compared with A$3.95 million for Microba and A$11,000 for BCAL.
The numbers do not settle the strategic question, but they explain why control of GSS’s cash reserves, commercial platform and proposed transaction has become the centre of the dispute. The company’s latest quarterly update had already placed its A$20.9 million cash balance and ongoing Microba merger proposal at the heart of the board fight.
The EGM Will Decide More Than Board Seats
Shareholders will now be asked to assess not only the BCAL nominees, but also the prospect of an immediate rupture among the existing directors if those nominees take a majority. GSS’s warning leaves open a consequential question: whether a successful spill would produce a new strategic plan, accelerate a BCAL-GSS merger, disrupt the proposed Microba deal, or some combination of the three.
Bottom Line?
The 28 October EGM has become a decision on board continuity and transaction strategy, with BCAL’s merger intentions still unresolved.
Questions in the middle?
- Will BCAL make the unequivocal statement about its merger intentions that GSS is demanding?
- Will the reported 23.3% combined holding affect voting dynamics or trigger further disclosure?
- If BCAL nominees gain a majority, how quickly would the current directors resign and what happens to the Microba proposal?